This inventor holds 2 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignee: Eli Lilly and Company. Active years: 2003-2025.
Company Filing History:
Years Active: 2003-2025
Title: Neil John Kallman: Innovator in Pharmaceutical Processes
Introduction
Neil John Kallman is a notable inventor based in Indianapolis, IN (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 2 patents. His work focuses on innovative processes and intermediates that enhance drug development.
Latest Patents
Kallman's latest patents include "Processes and intermediates for the preparation of 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl]ethenone." This invention provides processes and intermediates for the preparation of D1 PAM I: Formula (I). Another significant patent is "Formation and anion-exchange of crystalline echinocandin ammonium salts." This method describes forming a crystalline Echinocandin nucleus salt from its mixed broth and/or partially purified process streams through a series of steps, including nanofiltration and crystallization.
Career Highlights
Kallman is currently employed at Eli Lilly and Company, a leading pharmaceutical firm known for its innovative drug development. His work at Eli Lilly has allowed him to contribute to advancements in pharmaceutical processes that are crucial for the industry.
Collaborations
Throughout his career, Kallman has collaborated with notable colleagues, including Brian Weston Dalder and Michael Anthony Dotlich. These collaborations have further enriched his contributions to the field.
Conclusion
Neil John Kallman is a distinguished inventor whose work in pharmaceutical processes has led to valuable patents that enhance drug development. His contributions continue to impact the industry positively.